Expanding Portfolio

Oculis SA has agreed to license a topical anti-TNF alpha antibody from Novartis

Colin Kerr

Posted: Friday, February 1, 2019

Oculis SA has entered into an agreement to license a novel topical anti-TNF alpha antibody from Novartis.

The compound, LME 636, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. Efficacy and safety were evaluated in three clinical trials.

Dr Riad Sherif, Oculis CEO, said: “This agreement is part of our ongoing strategy to access multiple sources of technologies and compounds that bolster our portfolio of innovative products to treat eye diseases.”

Latest Articles

escrs members advert